Search research articles
Contact Us
Filters
Showing results (471-480 of 628) with videos related to
Page
of 63
Sort By:
Leukemia
|
February 16, 2011
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
M R Baer, S L George, B L Sanford, et al.
Bone Marrow Transplantation
|
January 25, 2005
A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease
T Hahn, M Benekli, C Wong, et al.
Pharmaceutics
|
July 24, 2020
Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs
John N Van den Anker, Susan McCune, Pieter Annaert, et al.
Plos One
|
February 18, 2014
Characterization of a novel glucokinase activator in rat and mouse models
Min Lu, Pingping Li, Gautam Bandyopadhyay, et al.
Blood
|
December 2, 2004
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
Joseph O Moore, Stephen L George, Richard K Dodge, et al.
Leukemia
|
April 16, 2025
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial
Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
March 29, 2019
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management
Najeebah A Bade, Crystal Lu, Ciera L Patzke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Maria R Baer, Aksinija A Kogan, Søren M Bentzen, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 8, 2023
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies
Manish R Patel, William Donnellan, Michael Byrne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 28, 2017
Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Shivani Kapoor, Karthika Natarajan, Patrick R Baldwin, et al.
Page
of 63
Search research articles
Search
Showing results (471-480 of 628) with videos related to
Sort By:
Page
of 63
Leukemia
|
February 16, 2011
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
M R Baer, S L George, B L Sanford, et al.
Bone Marrow Transplantation
|
January 25, 2005
A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease
T Hahn, M Benekli, C Wong, et al.
Pharmaceutics
|
July 24, 2020
Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs
John N Van den Anker, Susan McCune, Pieter Annaert, et al.
Plos One
|
February 18, 2014
Characterization of a novel glucokinase activator in rat and mouse models
Min Lu, Pingping Li, Gautam Bandyopadhyay, et al.
Blood
|
December 2, 2004
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
Joseph O Moore, Stephen L George, Richard K Dodge, et al.
Leukemia
|
April 16, 2025
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial
Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
March 29, 2019
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management
Najeebah A Bade, Crystal Lu, Ciera L Patzke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2022
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Maria R Baer, Aksinija A Kogan, Søren M Bentzen, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 8, 2023
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies
Manish R Patel, William Donnellan, Michael Byrne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 28, 2017
Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Shivani Kapoor, Karthika Natarajan, Patrick R Baldwin, et al.
Page
of 63